EPZ5676: Potent DOT1L Inhibitor Transforming Leukemia Res...
2025-10-18
DOT1L inhibitor EPZ-5676 delivers unparalleled specificity and potency for dissecting H3K79 methylation in MLL-rearranged leukemia models, setting a new standard for epigenetic research. Its robust activity and compatibility with advanced workflows empower researchers to unravel disease mechanisms, optimize therapeutic strategies, and streamline experimental troubleshooting.